July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: the BRDME study
Author Affiliations & Notes
  • Maartje J.C. Vader
    Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
  • Ann-Sofie M.E. Schauwvlieghe
    Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
  • Frank D Verbraak
    Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
  • Greetje Dijkman
    Ophthalmology, Leiden University Medical Centre, Leiden, Netherlands
  • Johanna M.M. Hooymans
    Ophthalmology, University Medical Center Groningen, Groningen, Netherlands
  • Leonie I. Los
    Ophthalmology, University Medical Center Groningen, Groningen, Netherlands
  • Aeilko H. Zwinderman
    Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
  • Tunde Peto
    Ophthalmology, Queens University Belfast, Belfast, United Kingdom
  • Carel B. Hoyng
    Ophthalmology, Radboud University Medical Center, Nijmegen, Netherlands
  • Redmer van Leeuwen
    Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands
  • Johannes R. Vingerling
    Ophthalmology, Erasmus Medical Centre, Rotterdam, Netherlands
  • Annette C. Moll
    Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
  • Janneke J.C. van Lith-Verhoeven
    Ophthalmology, Elisabeth - Twee Steden (ETZ) Hospital, Tilburg, Netherlands
  • Marcel G.W. Dijkgraaf
    Clinical Research Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
  • Reinier O. Schlingemann
    Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
    Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships   Maartje Vader, None; Ann-Sofie Schauwvlieghe, None; Frank Verbraak, None; Greetje Dijkman, None; Johanna Hooymans, None; Leonie Los, None; Aeilko Zwinderman, None; Tunde Peto, None; Carel Hoyng, None; Redmer van Leeuwen, None; Johannes Vingerling, None; Annette Moll, None; Janneke van Lith-Verhoeven, None; Marcel Dijkgraaf, None; Reinier Schlingemann, None
  • Footnotes
    Support  ZonMw, The Netherlands, Organisation for Health, Research and Development Grant 171202019
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3648. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maartje J.C. Vader, Ann-Sofie M.E. Schauwvlieghe, Frank D Verbraak, Greetje Dijkman, Johanna M.M. Hooymans, Leonie I. Los, Aeilko H. Zwinderman, Tunde Peto, Carel B. Hoyng, Redmer van Leeuwen, Johannes R. Vingerling, Annette C. Moll, Janneke J.C. van Lith-Verhoeven, Marcel G.W. Dijkgraaf, Reinier O. Schlingemann; Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: the BRDME study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3648. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Bevacizumab is widely used off-label as an alternative for the registered and more expensive anti-vascular endothelial growth factor (VEGF) agent ranibizumab in the treatment of diabetic macular edema (DME). We conducted a prospective, double-masked, randomized clinical trial to generate conclusive evidence on the non-inferiority of intravitreal bevacizumab compared to ranibizumab in patients with diabetic macular edema (Trialregister.nl NTR3247).

Methods : From June 2012 till February 2018, in 8 Dutch clinical centers, 170 participants were randomized to receive 6 monthly injections of either 1.25 mg bevacizumab (n=86) or 0.5 mg ranibizumab (n=84). Patients over 18 years of age, diagnosed with type 1 or type 2 Diabetes Mellitus, a glycosylated haemoglobin (HbA1c) of <12%, central area thickness on optical coherence tomography (OCT) of >325 microns and visual impairment due to DME with best corrected visual acuity (BCVA) of ≥ 24 letters and < 79 letters, were eligible for participation. Primary outcome was the change in BCVA from baseline to month 6 compared between both treatment arms, with a non-inferiority margin of 3.5 letters.

Results : Performing covariance analysis, the estimated difference in BCVA between treatment arms was 1.8 in favor of ranibizumab, with the lower bound of the one-sided 95% confidence interval of -3.6 letters, thereby exceeding the non-inferiority margin of 3.5 letters. The mean (± standard deviation) BCVA improved from baseline to 6 months with 4.9±6.7 letters in the bevacizumab group and 6.7±8.7 letters in the ranibizumab group, P = 0.094. Participants with an initial worse BCVA at baseline (≤68 letters, approximately ≤20/50) improved with 7.2±7.3 letters after 6 months when receiving bevacizumab and with 10.9±10.4 letters when receiving ranibizumab, however this difference was not significant (P = 0.109). Participants with an initial better BCVA at baseline (≥69 letters, approximately ≥20/40) improved with 3.4±5.8 letters in the bevacizumab group and with 4.1±6.1 letters in the ranibizumab group, P = 0.483.

Conclusions : This study shows that, based on the change in BCVA from baseline to month 6, inferiority of bevacizumab to ranibizumab could not be rejected. In addition, patients with a lower BCVA at baseline showed a trend for a better outcome with ranibizumab. Our study confirms the differential efficacy of anti-VEGF agents in the treatment of DME.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×